314 related articles for article (PubMed ID: 1909615)
1. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.
Sader HS; Erwin ME; Jones RN
Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):372-81. PubMed ID: 1327789
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of sparfloxacin compared with those of five other quinolones.
Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M
Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
[TBL] [Abstract][Full Text] [Related]
9. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
McCarter YS; Mazens-Sullivan MF; Bartlett RC
Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
[TBL] [Abstract][Full Text] [Related]
12. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
King A; Phillips I
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
[TBL] [Abstract][Full Text] [Related]
14. The in-vitro activity of temafloxacin compared with other antimicrobial agents.
King A; Bethune L; Phillips I
J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
Wise R; Andrews JM; Brenwald N
J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
Jones RN; Sanchez ML
Diagn Microbiol Infect Dis; 1994 Jan; 18(1):61-8. PubMed ID: 8026159
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of fleroxacin compared with three other quinolones.
Bremner DA; Dickie AS; Singh KP
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
[TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
[TBL] [Abstract][Full Text] [Related]
20. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
Verbist L
J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
